Publications
111
Citations
1,419
Est. group size
~14
Recurring co-author estimate
Active years
18
Publishing since 2009
Jason A. Hanna's research focuses on rare vascular and soft-tissue cancers, particularly angiosarcoma and epithelioid hemangioendothelioma, studying the genetic and molecular changes that drive their development. A major focus is the role of microRNAs (small molecules that regulate gene activity) and genes like DICER1 in tumor formation, with work extending into potential drug treatments such as enoxacin and combined PLK1/mTOR inhibitor therapies. The lab also studies how tumors can promote cancer development in surrounding, non-cancerous tissue through immune system interactions.
Publication output has grown substantially in recent years, rising sharply from a handful of papers annually before 2022 to dozens per year in 2023-2026.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Abstract LT007: YAP1::TFE3 fusion protein promotes transformation and EndMT plasticity in epithelioid hemangioendothelioma
Cancer Research · 2026
- Canonical microRNA loss drives tumor development, implicating therapeutic efficacy of enoxacin in angiosarcoma
RNA · 2026
- Non-cell-autonomous tumor promotion in DICER1 cancer predisposition
Developmental Cell · 2025
- <scp>YAP1</scp> :: <scp>TFE3</scp> mediates endothelial‐to‐mesenchymal plasticity in epithelioid hemangioendothelioma
Molecular Oncology · 2025
- Abstract 2851: YAP1-TFE3 fusion protein promotes EndMT in epithelioid hemangioendothelioma
Cancer Research · 2025
- Abstract 5974: Novel combinational therapeutic strategy in angiosarcoma through PLK1 and mTOR co-inhibition
Cancer Research · 2025
- Abstract 2786: Investigation on the role of tumor suppressive microRNAs in angiosarcoma
Cancer Research · 2025
- Canonical microRNA loss drives tumor development implicating therapeutic efficacy of enoxacin in angiosarcoma
bioRxiv (Cold Spring Harbor Laboratory) · 2025
- IBCL-1079: Waldenstrom Macroglobulinemia Complicated by Deposition of Non-Amyloid IgM Lambda in the Gastrointestinal (GI) Tract and Concomitant Cardiac AL (Lambda) Amyloidosis
Clinical Lymphoma Myeloma & Leukemia · 2025
- Genomic landscape and preclinical models of angiosarcoma
Molecular Oncology · 2024
- Abstract 5463: Germline <i>DICER1</i> loss promotes rhabdomyosarcoma via innate immune system
Cancer Research · 2024
- Design, Synthesis, and Evaluation of Trihalomethyl Ketone Derivatives of Neocarzilin A as Improved Antimetastatic Agents
ACS Bio & Med Chem Au · 2024
- Abstract PR013: Identification, therapeutic potential, and regulatory networks of tumor suppressing miRNAs in angiosarcoma
Molecular Cancer Therapeutics · 2024
- Abstract PR010: DICER1 cancer predisposition tumor promotion mediated non-cell autonomously via neutrophils and NETosis
Molecular Cancer Therapeutics · 2024
- Data from Biallelic <i>Dicer1</i> Loss Mediated by <i>aP2-Cre</i> Drives Angiosarcoma
2023
- Cancer Research×16
- Nature Communications×2
- Molecular Oncology×2
- bioRxiv (Cold Spring Harbor Laboratory)×2
- Clinical Cancer Research×2
- Bozhi Liu
Medicine · Purdue University West Lafayette
- Nadia A. Lanman
Medicine · Purdue University West Lafayette
- Annaleigh Benton
Medicine · Purdue University West Lafayette
- Ant Murphy
Medicine · Purdue University West Lafayette
- Claire M. Pfeffer
Medicine · Purdue University West Lafayette
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 20, 2026.
Claim or correct this profile